Criteria Caixa S.A.U. Takes $6.17 Million Position in Thermo Fisher Scientific Inc. $TMO

Criteria Caixa S.A.U. purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 15,220 shares of the medical research company’s stock, valued at approximately $6,171,000. Thermo Fisher Scientific accounts for about 0.7% of Criteria Caixa S.A.U.’s investment portfolio, making the stock its 19th biggest holding.

A number of other hedge funds and other institutional investors have also bought and sold shares of TMO. Brighton Jones LLC grew its position in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its position in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the last quarter. GAMMA Investing LLC grew its position in Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock worth $2,419,000 after acquiring an additional 877 shares during the last quarter. GPS Wealth Strategies Group LLC grew its position in Thermo Fisher Scientific by 33.5% during the 1st quarter. GPS Wealth Strategies Group LLC now owns 363 shares of the medical research company’s stock worth $181,000 after acquiring an additional 91 shares during the last quarter. Finally, West Branch Capital LLC grew its position in Thermo Fisher Scientific by 10.9% during the 1st quarter. West Branch Capital LLC now owns 3,008 shares of the medical research company’s stock worth $1,497,000 after acquiring an additional 296 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of analyst reports. UBS Group upped their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. HSBC reiterated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Redburn Partners set a $580.00 price target on Thermo Fisher Scientific in a research report on Wednesday. JPMorgan Chase & Co. upped their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Robert W. Baird upped their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $593.43.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 1.8%

Shares of NYSE:TMO opened at $524.95 on Friday. The company has a market capitalization of $198.23 billion, a price-to-earnings ratio of 30.36, a P/E/G ratio of 2.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The business’s 50-day moving average is $488.68 and its 200-day moving average is $447.94. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the business earned $5.37 EPS. The firm’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.